ADVM Stock News & Analysis | Latest Updates

Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 at 9:00am EDT.

August 6, 2025Corporate

ADVM News

Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $4

Chardan Capital Maintains Buy on Adverum Biotechnologies, Maintains $33 Price Target

HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target

Adverum Biotechnologies Q1 EPS $(2.25) Misses $(1.94) Estimate

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Chardan Capital Maintains Buy on Adverum Biotechnologies, Lowers Price Target to $33

RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $5

HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target

Adverum Biotechnologies Q4 EPS $(1.96) Misses $(1.38) Estimate

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec For Wet AMD

HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target

Adverum Biotechnologies Schedules Webcast For November 18 To Present 52-Week LUNA Phase 2 And 4-Year OPTIC Clinical Data, Along With Key Pivotal Program Design

RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $10

Adverum Biotechnologies Q3 2024 GAAP EPS $(1.30) Beats $(1.31) Estimate

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

Adverum Commences Mid-Stage Chronic Eye Disorder Candidate Study

Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration

Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD